Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No treatment, just data: new study maps inflammation in heart and kidney patients

NCT ID NCT06655493

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from Novo Nordisk looked at 756 adults in the Middle East who have heart disease with or without kidney disease. Researchers measured levels of a protein called hsCRP, which indicates inflammation throughout the body. Participants had one clinic visit and continued their usual care—no new treatment was given. The goal was simply to count how many people have high inflammation, which may help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

756 people

The number who actually took part.

Started

Nov 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A cohort of patients with HF and a cohort of patients with ASCVD and CKD in the Middle East

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF) Exclusion Criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Current participation (i.e., signed informed consent) in any other interventional clinical study. 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. Clinical evidence, or suspicion of, active infection within the last 60 days. 5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic inflammation (HSCRP)

Contacts and locations

Locations

  • Al Qassimi Hospital, Sharjah

    Sharjah city, 12345, United Arab Emirates

  • Almoosa Specialist Hospital

    Al Ahsa, 36342, Saudi Arabia

  • Cleveland Clinic Abu Dhabi

    Abu Dhabhi, 112412, United Arab Emirates

  • Dallah Hospital_Riyadh

    Riyadh, 12381, Saudi Arabia

  • Dr. Sulaiman Al Habib Medical Group- Olaya

    Riyadh, 12214, Saudi Arabia

  • Dubai Hospital

    Dubai, 7272, United Arab Emirates

  • Fujairah Hospital

    Fujairah, 12345, United Arab Emirates

  • Imperial college, Abu Dhabi

    Abu Dhabhi, 48338, United Arab Emirates

  • King Fahad Armed Forces, Jeddah

    Jeddah, 23311, Saudi Arabia

  • King Fahad Medical City

    Riyadh, 59046, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre, Jeddah

    Jeddah, 23433, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre, Riyadh

    Riyadh, 12713, Saudi Arabia

  • King Khaled University Hospital,King Saud Univ. Med. City

    Riyadh, 12372, Saudi Arabia

  • King Salman North Western Armed Force Hospital (NWAFH)

    Tabuk, 47512, Saudi Arabia

  • Mediclinic Abu Dhabi

    Abu Dhabhi, 46713, United Arab Emirates

  • Rashid Hospital

    Dubai, 4545, United Arab Emirates

  • SMC, Riyadh

    Riyadh, 13215, Saudi Arabia

  • Sheikh Khalifa Hospital Fujairah

    Fujairah, 12345, United Arab Emirates

  • Tadwai hospital

    Dubai, 123456, United Arab Emirates

  • Tawam Hospital (SEHA)

    Abu Dhabhi, 15258, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.